IXS - Innexus Biotechnology Inc (TSXV) - Page 46
|won't be in for long term I played Biotechs some time ago and got burned, play the Momo and get out before it is too late|
We are waiting for an update from the CEO which may or may not include news on the NCI collaboration. Everything else is rumour or hearsay or pumping...a lot of pumping. See the bottom of this chart for a timeline of pumps. It's impressive.
Here's a nice summary/overview of IXS over 2010 and where they are positioned.
It's no new information, and stuff that could probably be derived from the financial statements and MD&A anyways.
On the topic of bankruptcy, they were over the brink ages ago! I still don't know how they're moving ahead with the exception of offering 2.5 cent shares for debt every once in a while. The halt came as a result of one of the following:
10.9 Power of Market Integrity Officials
(1) A Market Integrity Official may, in governing trading in on the marketplace:
(a) delay, halt or suspend trading in a security at any time and for such period of time as such Market Integrity Official may consider appropriate in the interest of a fair and orderly market;
(b) refuse to allow any bid price or ask price to be recorded at any time if, in the opinion of such Market Integrity Official, such quotation is unreasonable or not in compliance with UMIR or any Policy;
(c) settle any dispute arising from trading in securities on the marketplace where such authority is not otherwise provided for in any requirement governing trading on the marketplace;
(d) vary or cancel any trade which, in the opinion of such Market Integrity Official, is unreasonable or not in compliance with UMIR or any Policy;
(e) vary or cancel any trade upon application of the buyer and seller provided such application has been made by the end of trading on the day following the day on which the trade was made or such earlier time as may be established in any Marketplace Rule of the marketplace on which the trade was executed;
(f) in respect of any trade which has not complied with the requirements of Part 5, correct the price of the trade to a price at which the trade would have complied with such requirement, or
(g) require the Participant to satisfy the better bid or offer up to the disclosed volume if the trade failed to comply with the requirements of Part 5;
(g.1) in respect of any trade of a principal order or non-client order that has not complied with the requirements of Rule 5.3, require the Participant to satisfy the client order at the price and up to the volume of the trade which failed to comply with the requirements of Rule 5.3.
(h) provide to any person an interpretation of any provision of UMIR and any Policy in accordance with the purpose and intent of the provision and shall ensure that any such interpretation is observed by such person;
(i) exercise such powers as are specifically granted to a Market Regulator or Market Integrity Official by UMIR and any Policy; and
(j) exercise such powers as are specifically granted to the Market Regulator by the marketplace where the marketplace is entitled to grant such powers.
InNexus Bio Announces Annual General Meeting to Be Held 24 May 2011
Last Update: 3/23/2011 7:53:00 PM
VANCOUVER, British Columbia, Mar 23, 2011 (BUSINESS WIRE) -- InNexus Biotechnology Inc. ( www.ixsbio.com ), a leading drug development company commercializing the next generation of antibodies based on its proprietary DXL(TM) and Transmab(TM) technologies, today announced its Annual General Meeting will be held May 24th, 2011.
The Company also announced today the reason for the trading halt of its common shares this week. During the second, third and fourth quarters of 2010, the Company inadvertently issued common shares in repayment of debt for a price equal to the then current market price but less than the TSX Venture Exchange established minimum amount of $0.05, resulting in 21,523,492 excess shares issued in contravention of TSX Venture Exchange policies. This situation prompted the TSX Venture Exchange to halt trading of the Company's common shares. The Company has worked with the TSX to remedy the situation in the following manner:
a. Approximately 8.3 million common shares will be returned to Treasury by the Company's principal lender. b. Approximately 750,000 common shares will be returned to Treasury by the Officers and Directors of the Company. c. Approximately 11.8 million shares will be returned to the Company by its lender when shares are issued to repay debt that is currently due or will be due in the next 60 days.
Additionally, the Company has agreed to not issue common shares for less than the minimum amount in the future. The Company has cooperated fully with the TSX in order to resolve the situation in a timely manner and expects resumption to trading as soon as possible.
ATTENTION: All Canadian Securities Regulatory Authorities
We advise of the following with respect to the upcoming Meeting of Security Holders for InNexus Biotechnology Inc.:
Meeting type: Annual General Meeting
Record Date for Notice of Meeting: 19-04-2011
Record Date for Voting: 19-04-2011
Beneficial Ownership Determination Date: 19-04-2011
Meeting Date: 24-05-2011
Can someone explain to me how this is still on halt, yet IXSBF - US Stock equivalent is trading high volumes?
There has been significant movement from 0.0088 to 0.055 today - over 400% change, yet there is still nothing happening on the cdn side.
I've also been following the public discussion and bloggings on Stockhouse, but wanted to know if anyone could tell me what the movement on the US side means, if it means anything at all.
InNexus Bio Hires New Chief Financial Officer
|Refer to a friend|
© Business Wire 2011
InNexus Biotechnology Inc. (TSX:IXS.V), a leading drug development company commercializing the next generation of antibodies based on its proprietary DXL™ and Transmab™ technologies, today announced that it has appointed Christie Amato as its Chief Financial Officer. Mrs. Amato replaces David Petulla and assumed her new position on May 9th 2011. She will oversee InNexus non-research and development administrative functions in
The Company also announced today that it has recaptured 9,008,413 of its common shares inadvertently issued in repayment of debt during the second, third and fourth quarters of 2010, prompting the TSX Venture Exchange to halt trading of the Company’s common stock as announced on 23 March 2011. The common shares were returned to the company and cancelled.
Mrs. Amato brings her broad financial and management experience to InNexus following a highly successful tenure with progressive accounting and corporate finance roles. During the past five years with her previous organization, she managed all accounting functions, financial reporting including international operations and sales, driving $110 million in annual revenue. In addition to her financial and operations experience, she has led numerous transactions during her career and has focused on mergers and acquisitions.
Mrs. Amato is a public accountant with a B.A. Business Administration (CIS) from Detroit College of Business. "InNexus will benefit greatly from the addition of Christie to our team," said Jeff Morhet, Chief Executive of InNexus. "Her considerable financial skills will be crucial as we expand our business development activities."
VANCOUVER, May 11, 2011 (Canada NewsWire via COMTEX) -- Trading resumes in:
Issuer Name: Innexus Biotechnology Inc. TSX-V Ticker Symbol: IXS Resumption Time: 5/12/11 09:30ET
To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/May2011/11/c3687.html
SOURCE: Investment Industry Regulatory Organization of Canada (IIROC)
SOURCE: Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions
Investment Industry Regulatory Organization of Canada, (416) 646-7299
Still holding those 2-cent shares. This might just give me an opportunity to sell them off. Then again, Penman (at SH) who posts as Aliboy here, claims that the BCSC is investigating IXS.
InNexus files for antibody eye drop patent
2011-06-15 08:47 ET - News Release
Mr. Jeff Morhet reports
INNEXUS BIOTECHNOLOGY FILES PATENT FOR NOVEL AMD THERAPEUTIC
InNexus Biotechnology Inc. has filed for patent protection covering a novel antibody product for age-related macular degeneration (AMD) and other eye disorders.
InNexus's new treatment has activity against the angiogenic growth factor VEGF, well implicated in AMD. The Company has already developed and tested the treatment at body temperature and begun longer-term testing for mass production and shelf life, and its manufacturing method is robust yet simple. The product is intended for use as a topical therapy (eye drop) for eye disorders such as AMD and Diabetic Retinopathy.
AMD is a disease that causes significant vision loss in millions of Americans. More than 10 million suffer from various forms of this potentially sight-stealing disease, more than glaucoma and cataracts combined, according to the American Macular Degeneration Foundation. By 2020, as the population ages, that number is expected to double to near epidemic levels.
InNexus' product, designated IXSVEGF, is an antibody fragment, and this small protein has been modified by strategically mutating key residues to give stability at body temperature and by addition of a proprietary sequence to promote unique cellular penetration of the eye.
Tom Kindt, CSO of InNexus, says, "The protein engineering used to develop IXSVEGF has resulted in a product to treat ocular diseases that involve angiogenesis driven by VEGF and is intended to do so without invasive application steps such as direct injection into the eye. We have expressed IXSVEGF in good yield from prokaryotic cell cultures, and it remained properly folded through its isolation and purification. IXSVEGF binds its antigen target with high affinity, and studies indicate its ability to inhibit VEGF-induced proliferation of cells dependent on this factor."
Jeff Morhet, CEO, says, "We are confidant that IXSVEGF will fill a needed role in this large and expanding market and that the simple manufacturing process will result in a cost competitive entry to the field."
We seek Safe Harbor.